Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ChromaDex Corp Market Cap
The ChromaDex Corp (CDXC) share price is expected to increase by 18.45% over the next year. This is based on calculating the average 12-month share price estimate provided by 5 stock analysts who have covered CDXC. Price targets range from $5 at the low end to $12 at the high end. The current analyst consensus for CDXC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
ChromaDex Corp has a total of 5 Wall St Analyst ratings. There are 5 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that ChromaDex Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CDXC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sean McGowan Roth MKM | Buy | $8 | Maintains | Nov 6, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $8 | Maintains | Nov 4, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Reiterates | Aug 9, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Reiterates | Jul 15, 2024 |
| Sean McGowan Roth MKM | Buy | $6 | Maintains | Jun 12, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Reiterates | May 9, 2024 |
| Sean McGowan Roth MKM | Buy | $6 | Maintains | Apr 9, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Maintains | Mar 11, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 10, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | Jun 5, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Maintains | Mar 13, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5.5 | Reiterates | Feb 1, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5.5 | Maintains | Aug 29, 2022 |
| Brian Nagel Oppenheimer | Perform | Downgrade | Aug 16, 2022 | |
| Jeff Van Sinderen B. Riley Securities | Neutral | $2.4 | Downgrade | Aug 11, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Maintains | Jun 7, 2022 |
| Jeff Van Sinderen B. Riley Securities | Buy | $6 | Maintains | May 13, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $8 | Maintains | Apr 18, 2022 |
| Jeff Van Sinderen B. Riley Securities | Buy | $8 | Maintains | Mar 10, 2022 |
Roth Capital | Buy | Initiates | Mar 8, 2022 |
When did it IPO
2008
Staff Count
106
Country
United States
Sector/Industry
Consumer Defensive/Packaged Foods
CEO
Mr. Robert N. Fried
Market Cap
$513.3M
In 2023, CDXC generated $83.6M in revenue, which was a increase of 15.99% from the previous year. This can be seen as a signal that CDXC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - ChromaDex Corp. (NASDAQ:CDXC) has been named to Inc. 2024's Best in Business list in the Health Products category, highlighting its achievements in NAD+ research and healthy aging products.
Why It Matters - ChromaDex's inclusion on the Inc. 2024 Best in Business list highlights its industry leadership and credibility, potentially boosting investor confidence and interest in its growth prospects.
Fri, 22 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ChromaDex (CDXC) is currently at a 52-week high. Investors are evaluating the company's fundamentals to assess potential future gains.
Why It Matters - ChromaDex reaching a 52-week high indicates strong market performance, but analyzing fundamentals will reveal if growth can continue, impacting future investment decisions.
Thu, 21 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ChromaDex (CDXC) has passed the "Recent Price Strength" screening, indicating it may be a viable investment option for those seeking stocks with upward momentum.
Why It Matters - ChromaDex's recent price strength indicates momentum, suggesting potential for profit as it attracts investor interest and could outperform competitors.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - ChromaDex Corp. (NASDAQ: CDXC) announces its Niagen® ingredient is featured in Longevity.Technology's new supplement, aimed at promoting healthy aging by enhancing NAD+ levels.
Why It Matters - ChromaDex's partnership with Longevity.Technology highlights the growing demand for health supplements, potentially boosting CDXC's market position and revenue from its flagship product, Niagen.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ChromaDex (CDXC) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to assess its suitability.
Why It Matters - ChromaDex's potential as a momentum stock could influence trading strategies and attract interest, impacting its share price and market perception.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - ChromaDex (NASDAQ: CDXC) has launched its Niagen® IV product nationwide, now available at over 200 Restore Hyper Wellness locations, enhancing access to its NAD+ therapy.
Why It Matters - ChromaDex's nationwide rollout of Niagen IV expands its market reach and could drive revenue growth, enhancing investor confidence in future performance and stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
